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Background: We compared the diagnostic accuracy of
brain natriuretic peptide (BNP) and amino-terminal
proBNP (NT-proBNP) for diagnosis of preclinical and
mild heart failure (HF).
Methods: We assayed plasma NT-proBNP and BNP in
182 healthy controls and in a prospective cohort of 820
HF patients divided according to the American Heart
Association/American College of Cardiology classifica-
tion. These included 86 patients in stage A [mean (SE)
ejection fraction 61% (1%); mean (SE) age 47 (2) years],
255 in stage B [65% (2%); 62 (1) years], 420 patients in
stage C [35% (1%); 68 (1) years] and 59 in stage D [25%
(1%); 74 (1) years]. Diagnostic accuracies of BNP and
NT-proBNP were evaluated by ROC analysis, and a
multivariate linear regression model was applied to
predict HF staging.
Results: Median BNP and NT-proBNP concentrations
increased from stage A to D 57-fold and 107-fold, respec-
tively. Both assays were accurate (P <0.001) in separat-
ing stage B from controls or stage A, and stage C from
controls or stage A or B. NT-proBNP was more accurate
(P <0.001) than BNP in differentiating stage C from
stages A and B patients and controls and was a better
predictor of HF classification in a model including age,
sex, and renal function (P <0.001).
Conclusions: Monitoring BNP or NT-proBNP enabled
identification of asymptomatic patients at risk for the
development of HF. NT-proBNP showed better accuracy
than BNP for identifying mild HF.
© 2007 American Association for Clinical Chemistry
The role of natriuretic hormones in identification of
asymptomatic ventricular dysfunction remains to be clar-
ified (1, 2). Brain natriuretic peptide (BNP)3 and amino-
terminal pro–brain natriuretic peptide (NT-proBNP) as-
says have been confirmed to be useful (2 ) for screening of
heart disease (3 ), stratification of patients with heart
failure (HF) (4, 5), detection of left ventricular systolic
and/or diastolic dysfunction (2 ), and differential diagno-
sis of dyspnea (6, 7). The use of BNP and NT-proBNP for
ruling out noncardiac dyspnea in HF assessment was
proposed by recent American and European guidelines
(8–11).
Because BNP and NT-proBNP show different bio-
chemical and physiological characteristics, monitoring
BNP and NT-proBNP may give different clinical results
(1, 2, 12, 13). A few studies have shown conflicting re-
sults regarding the diagnostic accuracy of BNP and
NT-proBNP in patients with chronic stable (14–25) and
acute (26–35) HF. These studies show wide heterogeneity
of the BNP and NT-proBNP immunoassays used, clinical
characteristics of patients, clinical end-points, and clinical
standards used for HF diagnosis, but all of the studies
used the New York Heart Association (NYHA) classifica-
tion for the stages of HF.
The American Heart Association/American College of
Cardiology (AHA/ACC) task force for the diagnosis and
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management of chronic HF has proposed a new classifi-
cation, updated in 2005 (11 ), focusing on the preclinical
evolution of the disease. In this classification, stage A
includes asymptomatic patients at risk for developing HF
with no structural cardiac involvement, stage B includes
asymptomatic patients at risk for developing HF with
structural cardiac involvement, stage C includes patients
with past/current symptoms of HF associated with struc-
tural heart disease, and stage D includes symptomatic
patients with end-stage disease requiring specialized
treatment strategies such as mechanical circulatory sup-
port, continuous inotropic infusions, cardiac transplanta-
tion, or hospice care. This classification is intended to
complement the NYHA classification, which primarily
gauges the severity of symptoms in stage C or D patients.
Our aim was to compare the diagnostic accuracy of
BNP and NT-proBNP assays across a wide variety of
patient populations, from asymptomatic individuals with
clinical conditions that put them at risk for HF (AHA/
ACC stage A–B), to patients with no, mild, or severe
symptoms associated with mild-to-severe systolic dys-
function (C–D).
Materials and Methods
patients
From February 1998 to January 2006 we prospectively
evaluated 820 consecutive patients referred to our cardio-
vascular medicine department for the evaluation of risk or
presence of HF. The diagnosis of HF was determined in
accordance with the ESC and AHA/ACC recommenda-
tions (9–11). Cardiac morphology and function were
assessed by 2-dimensional echocardiography. All patients
were stratified according to AHA/ACC classification.
Stage C and D patients were stratified according to NYHA
class and left ventricular ejection fraction (EF) (9–11).
Diagnosis of HF and classification of AHA/ACC HF
stages A through D, determined by history, symptoms,
and physical and instrumental findings for the assessment
of structural myocardial involvement, were established
by expert cardiologists blind to BNP and NT-proBNP
findings.
A control group, n  182 healthy individuals, was free
from disease and denied drug intake during the 4 weeks
before the study. In controls 50 years old, an echocar-
diogram and an effort stress test were performed to
exclude asymptomatic heart disease.
The investigation conformed to the principles outlined
in the Declaration of Helsinki and was approved by our
Institutional Ethics Committee. Informed consent was
obtained from all participants enrolled in the study.
bnp and nt-probnp assays
Blood was collected between 8 AM and 9 AM from study
participants after they had fasted overnight and rested in
a supine position for 20 min. Immediately after collection,
samples (8–10 mL) were placed in ice-chilled disposable
polypropylene tubes containing aprotinin (500 000 IU/L
of plasma) and EDTA (1 g/L of plasma). Plasma samples
were obtained shortly after venipuncture by centrifuga-
tion at 1500g for 15 min at 4 °C and, if not assayed
immediately, were frozen and stored at 20 °C in 0.5-mL
aliquots in polypropylene tubes. Both assays were per-
formed within 1 month of sample collection.
NT-proBNP was measured by the Elecsys® 2010 ana-
lyzer (Roche Diagnostics) (12, 13) and BNP was measured
with the 2-site IRMA method (Shionoria BNP), as de-
scribed previously (12, 13). The analytical performance of
electrochemiluminescence immunoassay (ECLIA) and
IRMA methods, as tested in our laboratory, was previ-
ously reported in detail (12, 13). Total imprecisions were
4.0% (103 ng/L) and 3.8% (601 ng/L), respectively. For
BNP, total imprecision was 11.0% (5 ng/L) and 9.0% (58
ng/L), respectively. The person executing and reading the
tests was blind to clinical diagnosis.
statistical analysis
Statistical analysis was carried out using the SPSS 12.0
software (SPSS). Because BNP and NT-proBNP values do
not show gaussian distribution in healthy individuals or
in patients with HF (1, 2, 12, 13), natural logarithmic
transformation of data was used for statistical analysis.
Both the original (using nonparametric tests) and the
logarithmically transformed (using parametric tests) data
were used for statistical analysis, but only the results
obtained with parametric tests after log transformation
were reported here, because the parametric approach
showed the same trend but with greater statistical power
than the respective nonparametric tests. Differences
among independent groups were analyzed by ANOVA.
Linear regression analysis was performed to assess the
relationship among peptides and other variables. The
diagnostic accuracy of BNP and NT-proBNP was quanti-
fied in terms of area under the ROC curves. A significant
difference in the area under the curve (AUC) defined the
increment in predictive power between different models.
ROC curve analysis furnished optimum cutoff values of
BNP and NT-proBNP concentrations (at the point of ROC
corresponding to maximal sum of specificity and sensi-
tivity), as well as corresponding sensitivity, specificity,
and positive and negative predictive value (PPV and
NPV, respectively).
The statistical significance of AUC differences between
BNP and NT-proBNP findings for each comparison were
also computed by comparing AUC values and the SE.
To tease out the influence of age, sex, and renal
function (estimated creatinine clearance by the Cockroft–
Gault formula) as confounders of the relationship with
NT-proBNP and BNP vs HF classification, a multiple
logistic regression model was also used. The overall
c-statistic (c-s) of the model was computed to assess the
respective influence of either NT-proBNP or BNP. P0.05
was considered significant.
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Results
clinical and demographic characteristics of
the study population
Characteristics of patients in various HF stages, as well
as corresponding BNP and NT-proBNP concentrations,
are summarized in Table 1. The stage A group included
86 patients [mean (SE) age 47 (2) years, range 15–84
years] who had normal left ventricular systolic and
diastolic function but were affected by risk factors
and/or clinical conditions prone to HF, including arte-
rial hypertension and diabetes mellitus, but had no
evidence of cardiac structural involvement at echocar-
diographic evaluation. The stage B group included 255
patients [age 62 (1) years, range 25–90 years] with
structural alterations (including left ventricular hyper-
trophy and/or diastolic dysfunction) but without HF
symptoms or left ventricular systolic dysfunction. As-
sociated clinical conditions were arterial hypertension,
diabetes mellitus, ischemic heart disease, and cardiac
valve abnormalities. The stage C and D group included
479 patients [age 68 (1) years, range 24–94 years; 77%
males] with a history of symptoms of HF and an EF
50% [mean (SE) 32% (1%)]; 420 patients were in stage
C with past or current symptoms of HF associated with
underlying structural heart disease [age 67 (1) years,
range 24–94 years], and 59 patients were in stage D
with symptomatic end-stage disease requiring special-
ized treatment strategies [age 74 (1) years, range 41–91
years)]. Underlying cardiac diseases in the C and D
patients were idiopathic dilated cardiomyopathy in 230
patients (48%), ischemic cardiomyopathy in 199 pa-
tients (42%), and cardiomyopathy secondary to other
diseases in 50 patients (10%) [including systemic arte-
rial hypertension (n  15), cardiac valve abnormalities
(n  14), cardiotoxicity after chemotherapy (n  5),
myopathies (n  4), diabetes mellitus (n  3), alcohol
consumption (n  3), myocarditis (n  3), congenital
cardiac abnormalities (n  1), amyloidosis (n  1), and
chronic constrictive pericarditis (n  1)]. NYHA classi-
fication of the stage C and D patients was NYHA I, 54
patients, 12%; NYHA II, 224 patients, 47%; NYHA III,
137 patients, 29%; and NYHA IV, 59 patients, 12%.
Table 1. Demographic and clinical characteristics of patients classified according to the AHA/ACC heart failure
classification scheme.a
Stage A (86 patients) Stage B (255 patients) Stage C (420 patients) Stage D (59 patients)
Age, (years) 47 (2) 62 (1) 67 (1) 74 (1)
Sex, % males 56 50 54 77
BMI 27 (1) 28 (1) 27 (1) 25 (2)
HT, (%) 90 73 47 39
Diabetes, (%) 10 13 26 25
IHD, (%) 0 12 40 49
AF, (%) 4 17 41 72
CrCl 60 mL/min, % 4 17 41 72
EF, (%) 61 (1) 65 (4) 32 (1) 26 (1)
BNP, (ng/L) 11 (5–19) 20 (10–40) 165 (52–378) 404 (182–1012)
NT-proBNP, (ng/L) 43 (26–85) 88 (43–224) 1136 (379–2824) 4394 (1467–10 184)
a Age mean (SE), body mass index BMI; mean (SE), arterial hypertension (HT), creatinine clearance by Cockroft–Gault formula, ischemic heart disease (IHD), atrial
fibrillation (AF), left ventricular EF [mean (SE)], BNP and NT-proBNP values (median, 25th–75th percentile) in patients (pts) classified according to AHA/ACC
classification (11).
Table 2. Demographic and clinical characteristics of Stage C and D patients classified according to NYHA classification
and left ventricular ejection fraction value EF; mean  (SE).a
NYHA I–II EF > 35–50%
(139 patients)
NYHA I–II EF < 35%
(138 patients)
NYHA III–IV EF > 35–50%
(51 patients)
NYHA III–IV EF < 35%
(151 patients)
Age, years 61 (1) 62 (1) 68 (2) 70 (1)
Sex, % males 79 80 77 74
BMI 27 (1) 27 (1) 27 (1) 26 (1)
Diabetes, (%) 24 20 23 30
IHD, (%) 37 32 45 52
CrCl 60 mL/min, % 21 28 43 59
AF, (%) 5 12 18 15
EF, (%) 41 (1) 27 (1) 41 (1) 25 (1)
BNP, (ng/L) 59 (23–135) 208 (82–290) 342 (183–608) 399 (179–775)
NT-proBNP, (ng/L) 408 (184–1128) 1324 (568–2357) 3122 (1187–6746) 2994 (1269–6467)
a Age mean  (SE), body mass index BMI; mean  (SE), creatinine clearance by Cockroft–Gault formula, ischemic heart disease (IHD), atrial fibrillation (AF), BNP
and NT-proBNP values (median, 25th–75th percentile) in stage C/D patients (pts) classified according to NYHA class and EF value.
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Patients were stratified according to the disease sever-
ity by NYHA classification with corresponding BNP
and NT-proBNP concentrations (Table 2). EF values
were 35%–50% for 190 patients and 35% for 289
patients. Therefore, stage C and D patients were further
divided into 4 groups according to NYHA class and EF:
(a) 139 with no/mild symptoms (NYHA I–II) and mild
systolic dysfunction (EF 35%–50%), (b) 138 with no/
mild symptoms (NYHA I–II) and severe systolic dys-
function (EF 35%), (c) 51 with severe symptoms and
mild systolic dysfunction, and (d) 151 with severe
symptoms and severe systolic dysfunction.
Patient medications included monotherapy or polythe-
rapy with calcium blockers, -blockers, diuretics, or an-
giotensin-converting enzyme inhibitors; 58% of stage A
patients and 10% of stage B patients were free of medica-
tions. All stage C and D patients were treated with
restriction of water and sodium intake and multidrug
treatment (furosemide, 72% of patients; angiotensin-con-
verting enzyme inhibitor or angiotensin-receptor block-
ers, 90%; carvedilol/bisoprolol, 63%; spironolactone, 49%)
not stopped at the time of the study, for obvious ethical
reasons. In stage D patients, blood sampling for BNP and
NT-proBNP assays was obtained at hospital admission,
Fig. 1. Plasma BNP (left) and NT-proBNP (right) concentrations in (top panel) 182 controls and 820 patients with stages A–D of HF and controls;
(bottom panel) 479 stage C–D patients grouped according to NYHA class.
The 10th, 25th, 50th (median), 75th, and 90th percentiles are indicated as boxes and lines. Note that the peptide concentrations are reported in log scale. Significant
differences among different stages are also reported: top panels, *  P 0.001 vs B, C, D; †  P 0.001 vs C, D; §  P 0.001 vs D; bottom panels, *  P 0.001
vs NYHA I, II, III, IV; †  P 0.001 vs NYHA II, III, IV; §  P 0.001 vs NYHA III, IV.
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before the initiation of inotropic and vasodilatory intra-
venous support. The control group included 182 healthy
individuals [mean (SE) age 60 (2) years, range 18–85
years; 56% males].
peptide concentrations in controls and
patients stratified according to structural
stages a–d and nyha classification
Log-transformed concentrations of plasma BNP and NT-
proBNP were significantly correlated (logNT-proBNP 
1.67  1.05 logBNP, n  992, R 0.945, P 0.0001). Both
BNP and NT-proBNP concentrations increased progres-
sively (P0.001) from stage A to stage D (Fig. 1, top panel),
whereas no difference was found between controls and
stage A concentrations. NT-proBNP showed a greater
increase than BNP values (P 0.001). Compared with
controls, median NT-proBNP concentrations increased by
28- and 107-fold in stages C and D, respectively, and BNP
concentrations increased 20- and 57-fold, respectively.
Similar progressive increases in plasma concentrations
were observed when BNP and NT-proBNP were plotted
according to NYHA classifications in C and D patients
(Fig. 1, bottom panel). For both assays the control group
concentrations were significantly lower (P 0.001) than
those in patients at all NYHA stages. Furthermore, for
both assays significant differences (P 0.001) were found
among all NYHA class values.
evaluation and comparison of diagnostic
accuracy of bnp and nt-probnp assays:
diagnosis of early asymptomatic hf
Both BNP and NT-proBNP did not show significant
diagnostic accuracy for differentiating stage A patients
from controls [Table 3 and Fig. 2, top left panel, BNP, mean
(SE): ROC AUC 0.604 (0.038) vs NT-proBNP: AUC 0.531
(0.038)]. The diagnostic accuracies of both BNP and NT-
proBNP were significant (P 0.001), and comparable, for
separating stage B patients from controls [Fig. 2, top center
panel, BNP, AUC 0.768 (0.022) vs NT-proBNP: AUC 0.750
(0.023)] and stage A patients [Fig. 2, top right panel, BNP,
AUC 0.679 (0.031) vs NT-proBNP: AUC 0.696 (0.030)].
Both BNP and NT-proBNP showed significant (P
0.001) and comparable accuracy in diagnosing mild left
ventricular diastolic dysfunction [153 patients (60%) with
altered relaxation, early-to-late phase ratio 1, deceleration
time220 ms, isovolumetric relaxation110 ms] in stage B
patients [BNP: AUC 0.761 (0.026), cutoff 21 ng/L, sensitivity
49%, specificity 88%, PPV 55%, NPV 73% vs NT-proBNP:
AUC 0.748 (0.027), cutoff 21 ng/L, sensitivity 60%, specificity
82%, PPV 53%, NPV 77%, not significant (NS)].
evaluation and comparison of diagnostic
accuracies of bnp and nt-probnp assays:
diagnosis of symptomatic hf
The diagnostic accuracies of both BNP and NT-proBNP
were significant in patients with symptomatic HF
Table 3. Comparison of the diagnostic accuracy between BNP and NT-proBNP assays.a
Comparison Assay AUC, mean (SE)
Diagnostic
accuracy,
P value
Cut-off,
ng/L
Sensitivity,
%
Specificity,
%
PPV,
%
NPV,
%
BNP vs
NT-proBNP
comparison,
P value
Stage A vs controls BNP 0.604 (0.038) NS 9 60 58 41 76 NS
NT-proBNP 0.531 (0.038) NS 55 44 69 41 63
Stage B vs controls BNP 0.768 (0.022) P 0.001 13 69 67 75 61 NS
NT-proBNP 0.750 (0.023) P 0.001 70 60 81 82 60
Stage A vs stage B BNP 0.679 (0.031) P 0.001 13 68 63 85 41 NS
NT-proBNP 0.696 (0.030) P 0.001 68 60 70 86 38
Stage C vs controls BNP 0.941 (0.009) P 0.001 26 85 93 97 74 P 0.001
NT-proBNP 0.974 (0.006) P 0.001 122 93 95 97 87
Stage C vs stage A BNP 0.908 (0.013) P 0.001 28 85 84 96 54 P 0.001
NT-proBNP 0.956 (0.008) P 0.001 195 86 93 98 61
Stage C vs stage B BNP 0.840 (0.015) P 0.001 44 79 78 86 69 P 0.001
NT-proBNP 0.880 (0.013) P 0.001 264 82 80 86 75
Stage C (NYHA I–II, EF 35%–50%) vs
controls
BNP 0.870 (0.021) P 0.001 21 75 88 81 84 P 0.001
NT-proBNP 0.939 (0.015) P 0.001 100 86 91 86 91
Stage C (NYHA I–II, EF 35%) vs
controls
BNP 0.960 (0.012) P 0.001 26 89 93 90 93 P 0.05
NT-proBNP 0.989 (0.006) P 0.001 122 97 95 93 98
Stage C (NYHA III–IV, EF 35%–50%) vs
controls
BNP 0.997 (0.007) P 0.001 38 95 97 89 99 NS
NT-proBNP 1.000 (0.002) P 0.001 158 100 98 93 100
Stage C (NYHA III–IV, EF 35%) vs
controls
BNP 0.995 (0.004) P 0.001 38 98 97 97 99 NS
NT-proBNP 0.999 (0.002) P 0.001 220 98 100 100 99
a Comparison by ROC analysis of BNP and NT-proBNP in differentiating stage A and B patients from the control group, stage A from the stage B, stage C from the
control group and from stage A and B, and finally the stage C with no/mild (NYHA class I–II) or severe (NYHA class III–IV) symptoms and mild (EF, between 35% and
50%) or severe (EF, 35%) left ventricular systolic dysfunction from the control group.
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(P 0.001). NT-proBNP showed greater diagnostic accu-
racy (P 0.001) than BNP for differentiating stage C
patients from (a) controls [Table 3 and Fig. 2, bottom left
panel, BNP, AUC 0.941 (0.009) vs NT-proBNP, AUC 0.974
(0.006)], (b) stage A patients [bottom center panel, BNP:
AUC 0.908 (0.013) vs NT-proBNP: AUC 0.956 (0.008)], (c)
stage B patients [bottom right panel, BNP: AUC 0.840
(0.015) vs NT-proBNP: AUC 0.880 (0.013)].
For stratification of patients according to NYHA class
and EF values, the diagnostic accuracies of both BNP and
NT-proBNP were significant (P0.001), with NT-proBNP
accuracy significantly better when patients with no or
only mild current symptoms (NYHA classes I and II) were
compared with controls (Table 3 and Fig. 3), irrespectively
of EF [top left panel EF 35%–50%, BNP: AUC 0.870 (0.021)
vs NT-proBNP: AUC 0.939 (0.015), P 0.001; top right
panel EF 50%: BNP: AUC 0.960 (0.012) vs NT-proBNP:
AUC 0.989 (0.006), P 0.05)].
When the patients with severe HF (NYHA classes III
and IV) were considered, the 2 assays showed significant
(P 0.001) and comparable diagnostic accuracy, irrespec-
tively of EF [Table 3 and Fig. 3; bottom left panel EF
35%–50%: BNP: AUC 0.997 (0.007) vs NT-proBNP: AUC
1.000 (0.002), NS; bottom right panel EF 50%: BNP: AUC
0.995 (0.004) vs NT-proBNP: AUC 0.999 (0.002), NS].
predictors of acc-aha classification of hf
Multivariate logistic regression showed a significant in-
crease (P 0.01) in the c-s when BNP or NT-proBNP was
separately added to the starting model including age, sex,
and creatinine clearance, in predicting stage C vs control
group, stage A, or stage B. The c-s values were always
significantly higher for models including NT-proBNP
than BNP: stage C vs healthy condition, starting model
(age, sex, and creatinine clearance) c-s, 0.506, SE 0.037
(BNP c-s 0.713, SE 0.066 vs NT-proBNP c-s 0.877, SE 0.062;
P 0.05); stage C vs stage A: starting model c-s 0.703, SE
0.037 (BNP c-s 0.798, SE 0.033 vs NT-proBNP c-s 0.876, SE
0.027; P 0.05); stage B vs stage C: starting model c-s
0.607, SE 0.031 (BNP c-s 0.702, SE 0.029 vs NT-proBNP c-s
0.804, SE 0.026; P 0.01).
Discussion
This study evaluated the diagnostic accuracy of B-type
natriuretic peptides in a large spectrum of patients at risk
for HF, either without or with structural myocardial
involvement. Present findings confirm that BNP and
NT-proBNP share a clinically relevant diagnostic accu-
racy in HF patients (2 ) and suggest a significant difference
in diagnostic accuracy between BNP and NT-proBNP,
depending on the type of population studied. Another
Fig. 2. ROC analysis of BNP and NT-proBNP in differentiating (top panel) stage A patients from controls (left), stage B from controls (center), stage
A from stage B (right); (bottom panel), and stage C from controls (left), stage A (center), and stage B (right).
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main finding is that cutoff concentrations are dependent
on the study population and/or on the reference group
studied. Our results demonstrate that the measurement of
BNP or NT-proBNP is useful in stratifying patients ac-
cording to the HF stages as suggested by AHA/ACC
guidelines (11 ). In particular, both BNP and NT-proBNP
showed diagnostic accuracy in separating out either
asymptomatic ventricular impairment (stage B) vs con-
trols or stage A patients. Moreover, BNP and NT-proBNP
assays enabled differentiation of those patients with no or
mild symptoms of disease (stage C, NYHA class I–II) from
controls or stage A–B patients. For these clinical condi-
tions, our study suggests that NT-proBNP has a better
diagnostic accuracy than BNP, including a model based
on age, sex, and renal function.
We have chosen for the present study the ECLIA
method for NT-proBNP and the IRMA method for BNP,
although the latter is not commonly used. Indeed, a
Fig. 3. ROC analysis of BNP and NT-proBNP corresponding to comparison between healthy controls and (a) patients with no or mild symptoms of
HF (NYHA class I–II) and mild/moderate systolic dysfunction (EF between 35% and 50%; top left panel), (b) NYHA class I–II patients and severe
systolic dysfunction (EF35%; top right panel), (c) NYHA class III–IV patients with EF between 35% and 50% (bottom left panel), and (d) NYHA class
III–IV patients with severe systolic dysfunction (EF 35%; bottom right panel).
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previous multiassay comparison from our laboratory,
between ECLIA NT-proBNP assay and several BNP im-
munoassays, indicated that the ECLIA NT-proBNP assay
had a better diagnostic accuracy in detecting patients in
the early stage of HF (NYHA class I–II), and that the
IRMA BNP method showed better performance com-
pared with other commercial immunoassays for BNP
(12, 13). Results of several recent studies suggest that the
diagnostic accuracy of BNP depends not only on the
peptide measured but also on the platform used
(2, 12, 13, 36–38). Commercial BNP immunoassays use
different standard materials and antibodies, specific for
different epitopes (2, 12, 13, 36–38). Therefore, BNP re-
sults may significantly vary dependent on the assay used
(2, 12, 13, 36–38). On the other hand, all fully automated
NT-proBNP assays, using standard materials and anti-
bodies harmonized against the Roche system, should
likely give more homogeneous results, although this has
not yet been proven.
The findings of the present study confirm that cutoff
concentrations depend on the method as well as on the
population studied (2, 12, 13, 36–38). For this reason it is
impossible to suggest a specific cutoff concentration as
valid for all clinical settings. In particular, because of their
high NPVs, low concentrations of BNP (40 ng/L) and
NT-proBNP (160 ng/L) should be used as cutoffs to
differentiate healthy individuals or asymptomatic pa-
tients (stage A–B or NYHA class I) from patients with
symptoms of HF (i.e., for the rule-out; Fig. 2). More
precise methods might show better diagnostic accuracy
than IRMA compared with the ECLIA method. For this
reason and for the differences in diagnostic accuracy
among commercial BNP methods (12, 13), the cutoff con-
centrations found in the present study cannot be applied
in other clinical settings, and findings on the IRMA assay
might not be directly applicable to other BNP assays.
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